Lake Street assumed coverage of Beta Bionics (BBNX) with a Buy rating and $30 price target The company has architected a best-in-class offering, optimal delivery channel, and R&D strategy supportive of long-term growth, according to the analyst, who does not think investors are ascribing enough value to the whole company strategy or the iLet’s “best-in-class” user simplicity and patient outcomes that “presents a one-size-fits-all ‘goldilocks’ proposition for Type 1s and Type 2s.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics initiated with an Outperform at Wolfe Research
- Beta Bionics initiated with a Neutral at Goldman Sachs
- Positive Developments and Strategic Advancements Drive Buy Rating for Beta Bionics, Inc.
- Beta Bionics Q1 2025 Earnings: Strong Growth and Optimism
- Strong Performance and Growth Potential: Buy Rating for Beta Bionics, Inc.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue